MedTrace Logo

Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease

NCT04718207 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2022-08-24

No results posted yet for this study

Summary

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

Conditions

  • Patients With Alzheimer's Disease

Interventions

DEVICE

Brain positron emission tomopgraphy (PET) - scan

Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-08-01
Completion
2022-02-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04718207 on ClinicalTrials.gov